Literature DB >> 23721779

Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA.

Viviana E Laurent1, Claudia Sampor, Verónica Solernou, Jorge Rossi, Mariano Gabri, Silvia Eandi-Eberle, Maria T G de Davila, Daniel F Alonso, Guillermo L Chantada.   

Abstract

AIM: To evaluate minimally disseminated disease (MDD) in cytologically negative cerebrospinal fluid (CSF) specimens of patients with high-risk retinoblastoma by the detection of the synthase of ganglioside GD2 mRNA by reverse transcriptase-polymerase chain reaction (RT-PCR).
METHODS: The CSF was evaluated in 26 patients with high risk for CSF relapse: 14 with postlaminar optic nerve invasion, five of them with tumour at the resection margin, five with massive choroidal invasion, three with overt orbital extension and four patients with systemic metastasis. Serial CSF examinations were repeated at different time intervals according to stage and in the event of suspected relapse. GD2 synthase mRNA was evaluated by RT and nested PCR at each procedure.
RESULTS: MDD was present at diagnosis in six cases (23%) and it was significantly associated to massive optic nerve involvement or history of glaucoma (p<0.05). Three of the children with positive MDD had a CSF relapse. Thirteen patients had negative MDD at diagnosis and one had a CSF relapse. In seven children no ARN could be obtained for PCR analysis and two subsequently relapsed. The probability of CSF relapse was 0.50 (95% confidence interval (CI) 0.13-0.88) for children with MDD and 0.08 (95% CI 0.02-0.46) for those with negative RT-PCR examination of the CSF at diagnosis (p=0.03).
CONCLUSIONS: MDD in the CSF detected by RT-PCR for GD2-synthase mRNA occurred in 31.7% of evaluable high-risk children with retinoblastoma with no initial central nervous system (CNS) involvement. It was significantly associated to optic nerve involvement and glaucoma and increased risk of CSF relapse.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GD2; Metastasis; Retinoblastoma

Mesh:

Substances:

Year:  2013        PMID: 23721779     DOI: 10.1016/j.ejca.2013.04.021

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  Retinoblastoma, the visible CNS tumor: A review.

Authors:  Helen Dimaras; Timothy W Corson
Journal:  J Neurosci Res       Date:  2018-01-03       Impact factor: 4.164

2.  Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation.

Authors:  Erin M Sullivan; Matthew W Wilson; Catherine A Billups; Jianrong Wu; Thomas E Merchant; Rachel C Brennan; Barrett G Haik; Barry Shulkin; Tammy M Free; Vickie Given; Carlos Rodriguez-Galindo; Ibrahim Qaddoumi
Journal:  J Pediatr Hematol Oncol       Date:  2014-08       Impact factor: 1.289

Review 3.  Management of retinoblastoma in children: current status.

Authors:  Guillermo Chantada; Paula Schaiquevich
Journal:  Paediatr Drugs       Date:  2015-06       Impact factor: 3.022

4.  First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment.

Authors:  Francis L Munier; Pascal Mosimann; Francesco Puccinelli; Marie-Claire Gaillard; Christina Stathopoulos; Susan Houghton; Ciara Bergin; Maja Beck-Popovic
Journal:  Br J Ophthalmol       Date:  2016-12-07       Impact factor: 4.638

5.  Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway.

Authors:  Huixue Wang; Jie Yang; Hui Pan; Mei Chee Tai; Mohamed H Maher; Renbing Jia; Shengfang Ge; Linna Lu
Journal:  Onco Targets Ther       Date:  2020-05-08       Impact factor: 4.147

6.  Cell-free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience.

Authors:  Prachi Kothari; Francesco Marass; Julie L Yang; Caitlin M Stewart; Dennis Stephens; Juber Patel; Maysun Hasan; Xiaohong Jing; Fanli Meng; Jeanette Enriquez; Kety Huberman; Agnes Viale; Jasmine H Francis; Michael F Berger; Neerav Shukla; David H Abramson; Ira J Dunkel; Dana W Y Tsui
Journal:  Cancer Med       Date:  2020-07-07       Impact factor: 4.452

7.  Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery.

Authors:  Paula Taich; Flavio Requejo; Marcelo Asprea; Mariana Sgroi; Pierre Gobin; David H Abramson; Guillermo Chantada; Paula Schaiquevich
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

8.  Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma.

Authors:  Santiago Zugbi; Daiana Ganiewich; Arpita Bhattacharyya; Rosario Aschero; Daniela Ottaviani; Claudia Sampor; Eduardo G Cafferata; Marcela Mena; Mariana Sgroi; Ursula Winter; Gabriela Lamas; Mariona Suñol; Manuel Daroqui; Edgardo Baialardo; Beatriz Salas; Anirban Das; Adriana Fandiño; Jasmine H Francis; Fabiana Lubieniecki; Cinzia Lavarino; Ralph Garippa; Osvaldo L Podhajcer; David H Abramson; François Radvanyi; Guillermo Chantada; Andrea S Llera; Paula Schaiquevich
Journal:  Cancers (Basel)       Date:  2020-09-22       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.